Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES versus FAYOSIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES versus FAYOSIM.
CHILDREN'S ZYRTEC HIVES vs FAYOSIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors, inhibiting histamine-mediated allergic reactions.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
5 mg or 10 mg orally once daily; maximum 10 mg/day.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 8-11 hours in healthy adults, allowing twice-daily dosing.
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
Cetirizine is primarily excreted renally (~60% unchanged), with ~10% fecal excretion.
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Category C
Category C
Antihistamine
Antihistamine